Healthcare provider profile · identity verified

Fernando Chedebeau, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1013115534

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Fernando Chedebeau, MD received $118.94 in general payments during 2025 across 5 reported records.

AstraZeneca Pharmaceuticals LP accounted for 44.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$118.94

5 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$53.10	44.6%	2	2025
Sumitomo Pharma America, Inc.	Unresolved — no canonical attribution shown	$46.34	39.0%	2	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$19.50	16.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$118.94	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
GEMTESA Normalized: gemtesa	Drug	Sumitomo Pharma America, Inc.	$46.34	2	2025
Source payment records 2025-09-11 · Sumitomo Pharma America, Inc. · $23.14 · Open Payments source 2025-12-11 · Sumitomo Pharma America, Inc. · $23.20 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$23.26	1	2025
Source payment records 2025-04-24 · AstraZeneca Pharmaceuticals LP · $23.26 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$19.50	1	2025
Source payment records 2025-09-02 · Amgen Inc. · $19.50 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	96	14
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	NEXIUM open payments reported associated product	CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180	Nexium · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	495	236
Vitamin D2	Ergocalciferol (Vitamin D2)	489	182
Losartan Potassium	Losartan Potassium	474	176
Famotidine	Famotidine	339	65
Gabapentin	Gabapentin	294	118
Metoprolol Succinate	Metoprolol Succinate	262	107
Amlodipine Besylate	Amlodipine Besylate	255	108
Simvastatin	Simvastatin	249	93
Metformin Hcl	Metformin Hcl	248	107
Omeprazole	Omeprazole	215	93
Pantoprazole Sodium	Pantoprazole Sodium	202	83
Levothyroxine Sodium	Levothyroxine Sodium	199	75
Lisinopril	Lisinopril	198	95
Eliquis	Apixaban	194	44
Rosuvastatin Calcium	Rosuvastatin Calcium	188	75
Tradjenta	Linagliptin	180	33
Benzonatate	Benzonatate	172	123
Temazepam	Temazepam	166	36
Furosemide	Furosemide	165	58
Nifedipine Er	Nifedipine	163	53
Alendronate Sodium	Alendronate Sodium	162	63
Albuterol Sulfate Hfa	Albuterol Sulfate	160	64
Hydrochlorothiazide	Hydrochlorothiazide	152	54
Prednisone	Prednisone	151	108
Xarelto	Rivaroxaban	140	30
Azithromycin	Azithromycin	139	111
Sildenafil Citrate	Sildenafil Citrate	135	34
Glipizide	Glipizide	132	54
Folic Acid	Folic Acid	126	70
Escitalopram Oxalate	Escitalopram Oxalate	122	52
Tamsulosin Hcl	Tamsulosin Hcl	119	58
Metoprolol Tartrate	Metoprolol Tartrate	113	53
Pravastatin Sodium	Pravastatin Sodium	113	34
Clonazepam	Clonazepam	108	35
Unifine Pentips	Pen Needle, Diabetic	102	21
Mirtazapine	Mirtazapine	101	30
Acetaminophen-Codeine	Acetaminophen With Codeine	99	51
Farxiga	Dapagliflozin Propanediol	96	14
Montelukast Sodium	Montelukast Sodium	90	44
Clopidogrel	Clopidogrel Bisulfate	86	40
Carvedilol	Carvedilol	85	43
Triazolam	Triazolam	85	27
Meclizine Hcl	Meclizine Hcl	84	43
Memantine Hcl	Memantine Hcl	84	41
Synthroid	Levothyroxine Sodium	81	14
Tadalafil	Tadalafil	75	24
Trazodone Hcl	Trazodone Hcl	75	27
Latanoprost	Latanoprost	74	27
Brimonidine Tartrate	Brimonidine Tartrate	73	15
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	72	28
Azelastine-Fluticasone	Azelastine/Fluticasone	71	18
Lantus	Insulin Glargine,hum.Rec.Anlog	69	13
Ibuprofen	Ibuprofen	66	43
Ammonium Lactate	Ammonium Lactate	65	49
Donepezil Hcl	Donepezil Hcl	65	34
Bumetanide	Bumetanide	63	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	63	25
Metformin Hcl Er	Metformin Hcl	63	28
Chlordiazepoxide Hcl	Chlordiazepoxide Hcl	62	18
Spiriva Respimat	Tiotropium Bromide	62	suppressed
Alprazolam	Alprazolam	61	19
Finasteride	Finasteride	61	30
Diclofenac Sodium	Diclofenac Sodium	60	37
Trueplus Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	60	14
Chlorthalidone	Chlorthalidone	55	21
Entresto	Sacubitril/Valsartan	54	12
Tramadol Hcl	Tramadol Hcl	53	23
Ketoconazole	Ketoconazole	52	38
Quetiapine Fumarate	Quetiapine Fumarate	52	21
Valsartan	Valsartan	52	24
Paroxetine Hcl	Paroxetine Hcl	51	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	48	40
Glipizide Er	Glipizide	45	19
Meloxicam	Meloxicam	45	31
Baclofen	Baclofen	44	31
Mupirocin	Mupirocin	44	33
Sucralfate	Sucralfate	44	17
Allopurinol	Allopurinol	43	11
Duloxetine Hcl	Duloxetine Hcl	39	14
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	37	suppressed
Insulin Aspart Flexpen	Insulin Aspart	36	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	35	suppressed
Cilostazol	Cilostazol	34	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	27
Fluticasone Propionate	Fluticasone Propionate	32	21
Lactulose	Lactulose	32	24
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	32	21
Fluconazole	Fluconazole	31	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	11
Jardiance	Empagliflozin	31	suppressed
Labetalol Hcl	Labetalol Hcl	31	13
Lorazepam	Lorazepam	31	suppressed
Sertraline Hcl	Sertraline Hcl	31	21
Triamcinolone Acetonide	Triamcinolone Acetonide	30	16
Irbesartan	Irbesartan	29	13
Ciclopirox	Ciclopirox Olamine	28	24
Hydralazine Hcl	Hydralazine Hcl	28	15
Methylprednisolone	Methylprednisolone	28	20
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	27	16
Crestor	Rosuvastatin Calcium	26	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Nitroglycerin	Nitroglycerin	26	suppressed
Trueplus Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	26	suppressed
Bupropion Xl	Bupropion Hcl	25	11
Ciclopirox	Ciclopirox	25	suppressed
Solifenacin Succinate	Solifenacin Succinate	25	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	24	18
Atenolol	Atenolol	23	13
Hydrocortisone	Hydrocortisone	23	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Nystatin	Nystatin	23	suppressed
Ranolazine Er	Ranolazine	23	suppressed
Timolol Maleate	Timolol Maleate	23	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	22	suppressed
Clobetasol Propionate	Clobetasol Propionate	22	15
Clonidine Hcl	Clonidine Hcl	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	21	17
Trueplus Pen Needle	Pen Needle, Diabetic	21	18
Calcitriol	Calcitriol	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Fenofibrate	Fenofibrate,micronized	20	suppressed
Spironolactone	Spironolactone	20	suppressed
Brilinta	Ticagrelor	19	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Glimepiride	Glimepiride	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	18	suppressed
Dapagliflozin	Dapagliflozin Propanediol	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	16
Ivermectin	Ivermectin	18	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	17	suppressed
Vascepa	Icosapent Ethyl	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	12
Buspirone Hcl	Buspirone Hcl	15	suppressed
Nexium	Esomeprazole Magnesium	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Procto-Med Hc	Hydrocortisone	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Azor	Amlodipine Bes/Olmesartan Med	13	suppressed
Benicar	Olmesartan Medoxomil	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Cephalexin	Cephalexin	13	12
Linzess	Linaclotide	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Norgestimate-Ethinyl Estradiol	Norgestimate-Ethinyl Estradiol	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Emtricitabine-Tenofovir Disop	Emtricitabine/Tenofovir (Tdf)	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Isentress	Raltegravir Potassium	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Lyrica	Pregabalin	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Testosterone	Testosterone	12	suppressed
Trueplus Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	11	suppressed
Lovaza	Omega-3 Acid Ethyl Esters	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Ursodiol	Ursodiol	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$118.94 · 5 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA, GEMTESA, REPATHA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error